I68.0
Conditions
Interventions
Group 1: The study is aimed at patients who have presented themselves due to a probable cerebral amyloid angiopathy (CAA) to an institution cooperating with the German Centre for Neurodegenerative Dis
initially in Bonn) and sleep diagnostics (initially in Bonn) are also planned.
Sponsors
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: - Fluency in German - Sufficient reading, writing, seeing and hearing ability for neuropsychological tests at the time of screening - Written informed consent - Presence of a relative who is willing to provide information about the participant throughout the study - Meeting Boston criteria 2.0 for probable CAA: 1) Age =50 years 2) Clinical presentation with spontaneous cerebral haemorrhage or TFNE(s) or cognitive impairment or dementia. 3) MRI features: a) =2 exclusively lobar haemorrhagic lesions in iron-sensitive MRI sequences, in any combination: cerebral haemorrhage, cerebral microhaemorrhages (CMB) or foci of cortical superficial siderosis (cSS) or convex subarachnoid haemorrhage. OR b) A lobar haemorrhagic lesion plus a white matter feature (severely dilated perivascular spaces in the centrum semiovale (i.e. >20 visible perivascular spaces in the centrum semiovale of one hemisphere) or white matter hyperintensities in a multispot pattern (i.e. >10 small circular or oval hyperintense lesions in the subcortical white matter of both hemispheres in the T2 weighting or FLAIR). (c) Absence of any deep haemorrhagic lesions (i.e. haemorrhage or CMB) in iron-sensitive MRI sequences. d) Absence of other causes of haemorrhagic lesions (haemorrhagic lesions in the cerebellum are not counted as either lobar or deep haemorrhagic lesions).
Exclusion criteria
Exclusion criteria: - Contraindication for MRI - Any disease that clearly interferes with participation in the study - Clinical diagnosis of another neurodegenerative disease - Participation in a clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •Structured recording of patients' previous illnesses, medication, course of illness, symptoms •Structured recording of self-report questionnaires •Clinical-neurological examination •Neuropsychological testing •Imaging examinations (MRT and OCT/OCT-A) •Examination of biomaterials | — |
Secondary
| Measure | Time frame |
|---|---|
| - Investigation of cardiovascular risk factors and comorbidities - Examination of perivascular clearance pathways - Examination of retinal anatomy and vascularisation | — |
Countries
Germany
Contacts
Public ContactGabor Petzold
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.
Outcome results
None listed